|
| Press Releases |
|
 |
|
| Wednesday, April 9, 2025 |
|
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
| SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
| Tuesday, April 16, 2024 |
|
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
| SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, August 14, 2023 |
|
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, June 12, 2023 |
|
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, May 22, 2023 |
|
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, December 19, 2022 |
|
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 4, 2022 |
|
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, August 24, 2022 |
|
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, July 8, 2022 |
|
|
SinoMab Received the Highest Subsidy from HKSTP |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
GTJAI Successfully Issued the First Publicly Offered Digital Bond of a Chinese Securities Firm
Aug 1, 2025 00:00 HKT/SGT
|
|
|
Shoucheng Buys Back 20M Shares in 2 Days, Signals Strong Bet
Jul 31, 2025 22:40 HKT/SGT
|
|
|
Over 20 Million Shares Repurchased in Two Days, Shoucheng Holdings Sends a Strong Signal with Decisive Action
Jul 31, 2025 20:11 HKT/SGT
|
|
|
Champion REIT Hosts ESG-Themed Event for a Third Year, Redefining Value and Sustainable Future of Commercial Properties Through Innovation 
Jul 31, 2025 20:10 HKT/SGT
|
|
|
Scipio Capital Advisors Capital Raise puts Alternative Asset Yield Within Reach of Accredited Investors
Jul 31, 2025 19:25 HKT/SGT
|
|
|
Revenue of LEQEMBI(R) (Preliminary Basis)
Jul 31, 2025 18:27 JST
|
|
|
New Report Reveals Key Considerations For Successful Distribution Onboarding
Jul 31, 2025 16:48 HKT/SGT
|
|
|
Transfer of Sharp Mie Plant No.2 and part of the land at Mie Base
Jul 31, 2025 17:11 JST
|
|
|
TANAKA PRECIOUS METAL GROUP Announces Business Partnership with JEPLAN to Realize a Decarbonized, Circular Society
Jul 31, 2025 15:00 JST
|
|
|
DENSO Announces First Quarter Financial Results
Jul 31, 2025 11:25 JST
|
|
|
Honda Launches All-New Prelude Teaser Page Ahead of Scheduled September 2025 Market Introduction
Jul 31, 2025 11:20 JST
|
|
|
MHI Demonstrates Transport of Relief Supplies in the Event of a Disaster Using Uncrewed Aerial Vehicles Currently in Development
Jul 31, 2025 11:00 JST
|
|
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Jul 31, 2025 9:30 JST
|
|
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
Jul 31, 2025 9:20 JST
|
|
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Jul 31, 2025 9:10 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
